Norditropin FlexPro Stungulyf, lausn 5/1,5 mg/ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 5/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 5/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 15/1,5 mg/ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 15/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 15/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 10/1,5 mg/ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 10/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 10/1,5 mg/ml

Sogroya Den Europæiske Union - islandsk - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - vöxtur - hinsveiflur og heilahimnubólur og hliðstæður - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 5 mg /1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg/1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg/1,5 ml

Skytrofa (previously Lonapegsomatropin Ascendis Pharma) Den Europæiske Union - islandsk - EMA (European Medicines Agency)

skytrofa (previously lonapegsomatropin ascendis pharma)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hinsveiflur og heilahimnubólur og hliðstæður - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

Saizen (Saizen LQ) Stungulyf, lausn í rörlykju 5,83 mg/ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

saizen (saizen lq) stungulyf, lausn í rörlykju 5,83 mg/ml

merck ab - somatropinum inn - stungulyf, lausn í rörlykju - 5,83 mg/ml

Saizen (Saizen LQ) Stungulyf, lausn í rörlykju 8 mg/ml Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

saizen (saizen lq) stungulyf, lausn í rörlykju 8 mg/ml

merck ab - somatropinum inn - stungulyf, lausn í rörlykju - 8 mg/ml